Immunomedics Inc.’s cancer drug Trodelvy, which received accelerated U.S. regulatory approval in April 2020, extended survival time in previously treated patients with an advanced form of breast cancer in a clinical trial.

Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Immunomedics announced that the company’s Phase III study involving Trodelvy met the primary endpoint of progression-free survival, as well as secondary endpoints, in patients with metastatic triple-negative breast cancer who have previously received at least two prior therapies.

Merck announced positive data from the Phase III KEYNOTE-355 trial looking at the company’s checkpoint inhibitor Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic triple-negative breast cancer.

Immunomedics Inc. won an accelerated approval from the U.S. Food and Drug Administration for Trodelvy, a therapy for a form of invasive breast cancer that has worsened despite two prior rounds of treatment.

Morris Plains, New Jersey-based Immunomedics halted the company’s Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC).